3. Recorded live on September 28th, 2023.
Stanford Medicine cardiologists Abha Khandelwal, MD and Joshua Knowles, MD delve into the nuances of lipoprotein (a), referred to as Lp(a), and how it relates to cardiovascular disease. Here, they explore Lp(a)'s structure, inheritance, distribution, and cardiovascular mechanisms, address screening, & current & emerging therapies for reducing Lp(a) levels. The discussion then extends to the link between elevated Lp(a), clinical risk, concluding with optimal treatments, control of risk factors and future developments such as emerging antisense oligonucleotide therapies.
Objectives
1. Recognize the relationship of lipoprotein (a), referred to as Lp(a), to cardiovascular diseases including ASCVD and aortic stenosis.
2. Apply guidelines on appropriate patients where Lp(a) should be measured and how often it should be measured.
3. Review the changing landscape of Lp(a) clinical trials.
4. Develop appropriate guideline based treatment recommendations for high Lp(a) patients to reduce ASCVD risk factors.
Claim CE credit at: [ Ссылка ]
